25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy.

Purpose: We addressed whether there is durable control of prostate cancer, defined as a prostate specific antigen cutoff of less than 0.2 ng/ml, greater than 20 years after irradiation for this disease. We also evaluated late recurrence, defined as recurrence after 10-year followup.

10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology.

Purpose: We documented the 10-year disease-free survival rate after simultaneous irradiation for prostate cancer and suggested standards for outcome calculation methodology.

Materials And Methods: From 1992 to 1998, 1,469 consecutive men with clinical stage T1T2NxM0 prostate cancer who did not receive neoadjuvant hormones were treated with simultaneous irradiation, an ultrasound guided transperineal prostate I seed implant followed by external irradiation. Median pretreatment prostate specific antigen (PSA) was 7.

Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.

Purpose: We report on the relationship of patient age to prostate specific antigen (PSA) bounce after brachytherapy for prostate cancer.

Materials And Methods: From 1992 to 1997, 1,011 consecutive men with stage T1-T2NxM0 prostate cancer were treated with simultaneous irradiation, transperineal prostate I-125 implant followed by external beam irradiation. No patients received neoadjuvant hormones.

Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer.

Purpose: A prostate specific antigen (PSA) cutoff point of 0.2 ng./ml.